Pfizer to Buy Canadian Drug Developer Trillium in $2.26 Billion Deal

Test tubes are seen in front of a displayed Pfizer logo in this illustration photo taken on May 21, 2021. (Reuters/Dado Ruvic/Illustration)
Share on facebook
Share on twitter
Share on whatsapp
Pfizer has announced plans to acquire Canadian drug developer Trillium Therapeutics Inc. in a $2.26 billion deal meant to boost Pfizer’s arsenal of blood cancer therapies. Under the deal, announced in an Aug. 23 press release, Pfizer will buy all outstanding Trillium shares at $18.50 apiece, representing a 118 percent premium on the stock’s 60-day weighted average price. In 2020, Pfizer acquired a $25 million stake in Trillium. Pfizer expects to b
Subscribe or log in to read the rest of this content.

Subscribe for Newsletter

Sign up to receive important news avoided by other media.

Scroll to Top